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Abstract
Background: Fo ¨rsters resonance energy transfer (FRET) microscopy is widely used for the analysis of protein interactions in
intact cells. However, FRET microscopy is technically challenging and does not allow assessing interactions in large cell
numbers. To overcome these limitations we developed a flow cytometry-based FRET assay and analysed interactions of
human and simian immunodeficiency virus (HIV and SIV) Nef and Vpu proteins with cellular factors, as well as HIV Rev
multimer-formation.
Results: Amongst others, we characterize the interaction of Vpu with CD317 (also termed Bst-2 or tetherin), a host
restriction factor that inhibits HIV release from infected cells and demonstrate that the direct binding of both is mediated by
the Vpu membrane-spanning region. Furthermore, we adapted our assay to allow the identification of novel protein
interaction partners in a high-throughput format.
Conclusion: The presented combination of FRET and FACS offers the precious possibility to discover and define protein
interactions in living cells and is expected to contribute to the identification of novel therapeutic targets for treatment of
human diseases.
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Introduction
One of the few non-invasive techniques to study protein
interactions is Fo ¨rsters resonance energy transfer (FRET) [1,2].
FRET is based upon the transfer of energy from an excited donor
fluorophor to a close-by acceptor fluorophor, resulting in enhanced
fluorescence emission of the acceptor [3]. This phenomenon only
occurs when the distance between donor and acceptor is less than
10 nm and the emission spectra of the donor overlaps with the
excitation of the acceptor [3]. While FRET-methods have been
improved in the last years [4,5], major limitations still exist. Due to
the spectral overlap between donor and acceptor it is difficult to
get a clear FRET signal and extensive controls and complicated
software calculations are needed to eliminate artefacts [6,7]. Other
FRET approaches that are less artefact prone, such as fluorescence
lifetime imaging (FLIM), require special equipment and expert
knowledge [8]. Most importantly, FRET measurements are
generally done by fluorescence microscopy, which is tedious and
essentially precludes the analysis of large cell numbers as well as
high-throughput-screening (HTS) for protein interactions [1,2].
One possibility to overcome these limitations is to detect and
quantify FRET signals by flow cytometry. Fluorescence activated cell
sorting (FACS) is non-invasive, sensitive and quantitative and allows
to measure large numbers of cells and samples in a reasonable
amount of time [9]. Thus, FACS-based FRET could be well suited to
study protein interactions in living cells. Surprisingly, this technology
was so far only applied to a few special scientific questions
[9,10,11,12,13]. The reason for this might be that an easy to adapt,
standardized, well controlled and reliable routine to measure and
quantify FRET by FACS is still missing. Our goal was to establish a
versatile FACS-based FRET assay using the standard FRET pair
CFP/YFP [14]. We evaluated this methodology by investigating
interactions between the human and simian immunodeficiency virus
(HIV and SIV) Nef and Vpu proteins and various cellular factors
[15], as well as HIV Rev multimerization [16]. Furthermore, we
demonstratethat HIV and SIV Nef bind to the primary viral receptor
CD4 with comparableefficiency. In contrast to this, SIV Nef interacts
w i t hC D 3t oam u c hh i g h e re x t e n ta sN e fo fH I V - 1d o e s .
Additionally, we show direct binding of HIV-1 Vpu to CD4 and
the recently described restriction factor CD317 (also termed Bst-2 or
tetherin), which inhibits retroviral particle release from infected cells
[17]. Mutation of amino acid residues in the membrane spanning
region of Vpu specifically diminished its capacity to bind CD317.
Finally, we demonstrate the applicability of our assay for HTS by
successful sorting of FRET positive cells and subsequent plasmid
isolation. The established method overcomes current limitations in
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9344proteomics, allowing scientists to identify and analyse protein
interactions in any compartment of living mammalian cells.
Materials and Methods
Generation and Cloning of Expression Vectors
Our aim was to develop a cloning strategy that allows to
generate any gene of interest (GOI) as an N- or C-terminal EYFP/
ECFP-fusion without further modifications of the vectors (Fig. S1).
Therefore, we used the widely distributed Clontech vectors
pEYFP-C1/N1 and pECFP-C1/N1 (kind gifts from Dr. Klaudia
Giehl, University of Ulm). In C1- and N1-vector derivatives C-
terminal tagged fusions can be generated by using the single cutter
restriction sites NheI and AgeI. Target sequence amplification is
done with 59-pNheI-GCGGCTAGC-(target sequence) and 39-pAgeI-
TCGACCGGTGCACCTGCTCC-(target sequence) which elimi-
nates the stop codon and introduces the linker AA sequence
GAGAPVAT. Similarly, N-terminal tagged fusions in C1-vector
derivatives can be generated by using the unique XhoI and EcoRI
sites and amplification of the target with 59pXhoI-CGCTCGAGCT-
(target sequence) and 39-EcoRI-CTGAATTC-(target sequence)
resulting in the linker SGLRSRA. In N1-vector derivatives N-
terminal tagged fusions are generated via the BsrGI and NotI
sites and the primer 59pBsrG1-GCTGTACAAGGGAGCAGGTG-
CAGGAGCA-(target sequence) and 39pNotI-GTCGCGGCCGCT-
(target sequence) resulting in the linker LYKGAGAGA. An
overview of the vectors and restriction sites used, as well as the
linker sites is depicted in Figure S1. The membrane expressed
pECFP-MEM (Clontech) control was a kind gift of Dr. Klaudia
Giehl (University of Ulm). As FRET-positive control we generated
the pEYFP-ECFP construct expressing EYFP and ECFP as a
fusion. Cellular factors (MHC-I, MHC-II, CD3f-chain, CD4,
CD317, MurrI and p53) were PCR amplified from a human PCR-
ready PBMC cDNA (Spring Bioscience) and ligated into pECFP-
C1 using standard cloning procedures. All factors were generated
as C-terminal tagged ECFP fusions except CD317, which was
tagged at the N-terminus. HIV-1 NL4-3 vpu, tat and NA7 nef as
well as SIVmac 239 nef were PCR amplified from proviral DNA
and ligated into pEYFP-N1 or pEYFP-C1 as C-terminal tagged
fusions. CD317 was PCR amplified and inserted into pFLAG-
CMV2 (Sigma) that directs the expression of CD317 N-terminally
tagged with a FLAG epitope. HIV-1 C-terminal tagged Rev-fusion
constructs were amplified by PCR from HIV-1 pcRevWT and
pcRevSLT40 [16] and ligated into pEYFP-N1 or pECFP-N1. For
demonstration of HTS, we PCR amplified the pEYFP-vpu fusion
and inserted it into the pCGCG-vector [18] instead of the IRES-
GFP cassette. All PCR derived inserts were sequenced to verify the
absence of undesired nucleotide changes.
Cell Culture and Transfections
293T or Hela cells were maintained in Dulbecco modified Eagle
medium (DMEM) supplemented with 10% FCS. 293T cells were
transfected by the calcium phosphate method as described
previously [18]. Briefly, 400,000 cells/well were seeded in 6-well
plates one day prior to transfection. Then we transfected 2.5 mg
DNA per donor and acceptor construct and FRET measurements
were performed 24–36 h post transfection. For the Rev multi-
merization experiments 293T cells were transiently transfected with
0.5 mg Gag expression vector GPV-RRE [19] (provided by M.H.
Malim; King’s College London, UK), 0.125 mg pBC12/CMV/
SEAP (transfection-efficiency control) and 0.25 mg of acceptor and
donor construct by using TurboFect reagent (Fermentas) according
to the manufactor’s protocol. Additionally to FRET measurements
supernatants were analysed for particle production by p24 antigen
ELISA and SEAP-activity 30 h post transfection. In some experi-
ments, we added coverslips to the wells to analyse subcellular
localization or FRET signals via confocal microscopy.
FACS-FRET and Confocal Microscopy
FACS-FRET measurements were performed using a FACSAria
(BD Bioscience) equipped with 405 nm, 488 nm and 633 nm
lasers. To measure ECFP and FRET cells were excited with the
405 nm laser and fluorescence was collected in the ECFP channel
with a standard 450/40 filter, while the FRET-signal was
measured with a 529/24 filter (Semrock). To measure EYFP,
cells were excited with the 488 nm laser while emission was also
taken with a 529/24 filter (Semrock). For each sample, we
evaluated a minimum of one thousand CFP/YFP positive cells
that fell within the background adjusted gate (Fig. 1a, panel 2). To
analyse subcellular localization or FRET via confocal microscopy,
transfected cells grown on coverslips were mounted on microscope
slides using mowiol mounting solution (2.4 g polyvinylalcohol, 6 g
Glycerin, 18 ml PBS) and imaged with a Zeiss LSM510 Meta.
Confocal FRET analysis were performed as described in the
‘‘FRET and colocalization analyzer – Users guide’’[7].
FACS-Analysis of Cell Surface Receptor Modulation
Jurkat cells were maintained in RPMI with standard supple-
ments and electroporated using the Microporator-MP100 (Peq-
Lab) device as recommended by the manufacturer. Briefly, 2610
6
cells per electroporation were washed twice with PBS and
resuspended in 100 ml R-buffer containing 5 mg Plasmid-DNA.
Microporator parameters were set to pulse voltage 1300, pulse
width 20 ms and number of pulses 2. Electroporated cells were
cultivated in 2 ml RPMI with standard supplements. 24 h later
cells were analysed via FACS for expression of CD4, MHCI and
CD3 as described previously [18].
Vpu-CD317 Co-Immunoprecipitation Experiments
For co-immunoprecipitation, 9610
5 293T cells were transfected
with pCMV-FLAG-CD317(0.1 mg)andpEYFP-vpu(1 mg) orpCG-
vpu (1 mg) expression plasmids as indicated. Cells were lysed by
digitonin lysis buffer (140 mM NaCl, 10 mM Tris/HCl, pH 7.4,
1 mM EDTA, protease inhibitor mixture (Roche), 1% (w/v)
digitonin (Calbiochem) in order to solubilize transmembrane pro-
teins. Cleared lysates were incubated with anti-Vpu serum [20] for
90 min on ice. Immune complexes were recovered on protein G-
Sepharose for 60 min, washed four times in wash buffer (lysis buffer
with 0.1%digitonin),separatedin15%SDS-PAA gel, and probed in
Western blot with M2-anti-FLAG-HRP antibodies (Sigma).
Library Screening for Potential Interaction Partners
293T or Hela cells were transfected as described above or
electroporated using the Microporator MP100 device (PeqLab) as
recommended by the manufacturer. For electroporation, 1 mg
total DNA (0.3 mg YFP construct and 0.7 mg CFP construct) was
mixed with 500,000 cells. Electroporations were carried out in
100 ml tips using the following conditions: 1200 V, 20 ms, 2 pulses
for 293T cells and 985 V, 35 ms, 2 pulses for Hela cells. One day
post transfection/electroporation FRET-positive cells were sorted
in PBS +1% FCS and pelleted. Plasmids were isolated via the
QIAamp DNA Micro Kit using the protocol for cultured cells as
provided by the manufacturer or the QIAprep Spin plasmid kit
(Qiagen) following the protocol ‘‘Isolation of plasmid DNA from
mammalian cells with QIAprep’’, which had better yields. Total
recovered DNA was transformed into One Shot TOP10 cells
(Invitrogen) and plated on a kanamycin containing agar plate.
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following restriction analysis of the insert.
Statistical Analyses
Statistical analyses were performed using the Graph Pad Prism
Version 5.0 software package. For all calculations we used the two-
tailed unpaired Students-t-test and the Mann-Whitney test, which
yielded the same results.
Results
Measurement of FRET by FACS
To establish an assay to measure FRET signals by FACS we first
analysed 293T cells expressing the CFP and YFP controls either
individually, in combination or as a fusion protein (Fig. 1a). We
gated on living cells according to forward and sideward scatter
(FSC/SSC) and adjusted photomultiplier tube (PMT) voltages and
compensation for CFP and YFP to specifically assess FRET in
double positive cells (Fig. 1a, panel 1). Importantly, when excited at
405 nm, YFP exhibited some emission in the FRET-channel.
Therefore, we introduced an additional gate to exclude cells from
further analysis that exert a false-positive signal in the FRET-
channel due to YFP only being excited at 405 nm (Fig. 1a, panel 2).
Subsequently, we plotted FRET versus CFP and introduced a
triangular gate to determine the amount of FRET-positive cells.
This triangle was adjusted to cells which were cotransfected with
CFP and YFP only and thus are FRET-negative (Fig. 1a, panel 3).
This gating strategy directly visualizes the sensitized acceptor
Figure 1. Setup of FRET-measurements by flow cytometry and microscopy. (a) The experimental setup and gating strategy to measure
FRET by FACS. Living 293T cells transfected with the controls CFPonly, YFPonly, CFP and YFP as well as the CFP-YFP fusion proteins were analysed on
a FACS Aria flow cytometer. Double positive cells were gated (panel 1) and false positive FRET signals resulting from YFP excitation by the 405 nm
laser were excluded (panel 2). The remaining cells were evaluated for FRET by adjusting a gate defining to cells which are cotransfected with CFP and
YFP only and should thus be FRET-negative (panel 3). (b) Living 293T cells and cells from the same transfections were treated with 2% PFA and
analysed for FRET as depicted in (a). Shown are mean values +/2 standard deviation from seven independent transfections. (c) 293T cells were grown
on cover slips and cotransfected with CFP and YFP or the CFP-YFP fusion protein and mounted on microscope slides. Confocal images were taken
and analysed for FRET using the ‘‘FRET and colocalization analyzer’’ ImageJ plug-in (7). ‘‘FRET’’-images give the calculated amount of FRET for each
pixel in the merged images. The ImageJ plug-in colour codes the relative FRET efficiency which is indicated by the displayed colour bar. Furthermore
the ‘‘coloc/FRET’’-plots display pixel colocalization as well as colour coded FRET efficiency in a 2D plot. CFP is shown in red and YFP in green.
doi:10.1371/journal.pone.0009344.g001
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Strikingly, only 0.1% of cells cotransfected with CFP and YFP
scoredFRET+ comparedto99.6%whencellsweretransfectedwith
a CFP-YFPfusion protein (Fig.1a, panel 3).Thus,this experimental
can distinguish real FRET signals from cross-talk artefacts.
Validation of FRET by Fluorescence Microscopy
For most FRET measurements via fluorescence microscopy
samples are fixed and mounted on cover slides. Therefore, we
evaluated the consequence of fixation with 2% paraformaldehyde
(PFA) on the FRET efficiency in our FACS assay. The amount of
FRET+ cells was reduced from 97.6% (+/2 1.1% SD) in the living
cell population transfected with the CFP-YFP fusion compared to
65.1% (+/210.7% SD) when cells were fixed (Fig. 1b). This
demonstrates that fixation attenuates FRET efficiency and highlights
the importance of assessing FRET measurements in living cells. To
confirm the results of our FACS-based FRET assay in an
independent setting, we performed confocal laser scanning micros-
copy on our positive (CFP-YFP fusion) and negative (CFP and YFP
cotransfected) controls. Confocal images were analysed with the
‘‘FRET and colocalization analyzer’’ ImageJ plug-in [7]. Cells
transfected with CFP and YFP together or the CFP-YFP fusion alone
showed intense and indistinguishable expression of both chromo-
phores in virtually all compartments of the cells (Fig. 1c). In contrast
to this, only cells that expressed the CFP-YFP fusion displayed a high
amount of colour-coded FRET (Fig. 1c), confirming the results
obtained with our FACS-based FRET assay (Fig. 1a and b).
Analysis of Protein Interactions in Living Cells
Next we wanted to exploit the methodology to assess the
binding of HIV-1 accessory proteins engaged in a variety of
interactions with cellular factors [21]. Lentiviral Nef and Vpu
proteins are important for efficient viral replication and AIDS
progression in vivo [15]. While it has been established that Nef and
Vpu manipulate the surface expression of different cellular
molecules, e.g. the primary viral receptor CD4 (Nef and Vpu) or
MHC-I (Nef), it is a matter of intense debate whether they are
modulated by direct binding to the receptors or through indirect
mechanisms [15,21,22,23,24]. To address this controversial issue,
we amplified genes encoding for CD4, CD3, MHC-I and II, p53
and CD317, all of which have been reported to be manipulated by
Nef and/or Vpu [15,22,23,24,25] and ligated them into the
pECFP-C1 fusion protein vector (Fig. S1). The well characterized
human and simian immunodeficiency virus nef (HIV-1 NA7,
SIVmac 239) [18,22,26] and vpu (NL4-3) [17,23,27] genes were
amplified and inserted into the pEYFP-N1 vector (Fig. S1),
thereby fusing EYFP to the respective C-terminus. To confirm
that the viral fusions are functional, we transfected Jurkat T-cells
and measured modulation of CD4, CD3 and MHC-I by Nef and
Vpu (Fig. S2). Furthermore we analysed the subcellular localiza-
tion of the viral as well as the cellular fusion proteins (Fig. S3).
These analyses showed that the Nef and Vpu fusions are
functional and exhibit the expected subcellular localization. Then
we cotransfected the cellular factors together with the Nef (HIV-1
NA7, SIVmac 239) or Vpu (NL4-3) fusion proteins in 293T cells
and performed FACS-based FRET on living cells (Fig. 2a and b).
Nef is predominantly targeted to the cell membrane, while Vpu is
located in the endoplasmic reticulum, the trans-Golgi-network and
the plasma membrane (Fig. S3) [15,22,23,24]. To address the
concern that high fluorophore concentration in a specific cellular
compartment (e.g. the membranes) might result in false positive
FRET signals, we cotransfected the Nef- and Vpu-YFP fusions
Figure 2. Analyses of protein interactions by FRET. (a) Representative primary FACS-plots showing the amount of FRET+ cells in living 293T
cells cotransfected with the indicated CFP and YFP fusion proteins. Numbers give total percentages of cells within the FRET gate (compare Fig. 1a
panel 3). (b) Mean values and standard deviations (SD) for the total amount of FRET+ cells from a minimum of eight independent experiments that
were analysed as depicted in (a). The dotted line gives the maximum background FRET-signal that was obtained when cells were cotransfected with
the MEM-CFP control and the YFP fusion proteins. Abbreviations: CfY, CFP fused YFP; CaY, CFPonly and YFP-fusion. (c) Merged images from confocal
pictures of 293T cells that were cotransfected with the Nef/Vpu-YFP fusion proteins (shown in green) and the indicated CFP-fusions (shown in red).
Regions in which both fusions colocalize appear yellow.
doi:10.1371/journal.pone.0009344.g002
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palmitoylated and preferentially stains cellular membranes (Fig.
S3) [28]. This additional negative control gave background FRET
signals ranging from 4.5% (+/23.1% SD; HIV-1 NA7 Nef) to
7.8% (+/23.9% SD; SIVmac 239 Nef) and 9.5% (+/24.5% SD;
HIV-1 NL4-3 Vpu) respectively.
We did not measure a significant FRET signal when Nef or Vpu
were expressed together with major-histocompatibility-complex
class I or II (MHC-I or II), the tumor suppressor p53 or Murr-I,
proposed to restrict HIV-1 replication in resting T-cells [29]
(Fig. 2a and b). In contrast, expression of SIVmac 239 Nef
together with the CD3f-chain resulted in 90.2% (+/27.4% SD)
FRET+ cells, indicating that both proteins interact (Fig. 2a and b).
Only SIV Nefs, but not HIV-1 Nef or Vpu have been reported to
down-modulate CD3 [15,22,26]. Thus, it has to be noted that
HIV-1 NA7 Nef 24.6% (+/28.6% SD) and NL4-3 Vpu 32.7%
(+/211.6% SD) also interacted with CD3f, albeit less efficiently
than SIVmac 239. This result might explain previous conflicting
reports concerning the ability of HIV-1 Nef to bind to CD3f
[30,31].
HIV-1 Nef and Vpu as well as SIV Nef have been reported
to interfere with the expression of the primary viral receptor CD4
by direct interactions [15,23,32]. In agreement with these pre-
vious reports, we confirm binding of HIV-1 NA7 Nef 42.1%
(+/211.7% SD), SIVmac 239 Nef 29.8% (+/29.8% SD) and
HIV-1 NL 4-3 Vpu 83.6 (+/26.2% SD) to CD4. Finally, we
investigated the potential interaction of the three viral proteins
with CD317. It has been shown that CD317 inhibits HIV-1
release from infected cells and that this restriction is counteracted
by Vpu [17]. Recent reports suggest that Vpu antagonizes CD317
via a beta-TRCP dependent pathway involving binding of CD317
to Vpu [33,34]. Using our FACS-based FRET assay we show that
coexpression of CD317 and Vpu results in 39.0% (+/218.1% SD)
FRET+ cells, strongly suggesting that both directly interact in
living cells. This interaction is specific, since Nef from HIV-1 NA7
7.9% (+/24.6% SD) and SIVmac 239 8.4% (+/2% 3.8 SD)
showed only background FRET signals (defined by the MEM-
control) in combination with CD317 (Fig. 2a and b). All data were
derived from at least eight independent experiments and the
reported differences are statistically highly significant compared to
the values obtained for the MEM-control (p,0.0001 for all cases
using two-tailed unpaired Students-t-test and Mann-Whitney-test).
Notably, we observed marked colocalization of some of the viral
proteins with cellular factors despite lack of a significant FRET
signal (Fig. 2c and Fig. S3; e.g. the MEM-control with NA7 and
mac 239 Nef). This further demonstrates that our assay is sensitive
to discriminate between mere co-localization in a subcellular
compartment and real FRET signals. In sum, these results
highlight the strength of our approach to characterize a variety
of protein interactions in living cells not only qualitatively, but also
in a quantitative manner.
Mapping of Interacting Domains by FACS-FRET
To investigate whether our assay allows to map interacting
domains within proteins, we analysed a variety of previously
described Vpu mutants [27] for their capacity to bind CD4 and
CD317 (Fig. 3). As demonstrated in Figure 2, expression of NL4-3
Vpu together with CD4 or CD317 resulted in a strong FRET-signal
(Fig. 3a and b). Mutation of one (US52A) or both (UM2/6) of the
serine residues in Vpu that have been shown to be phosphorylated
by casein-kinase-2 (CK-2) [23,35] did not reduce the frequency of
FRET+ cells. In contrast, deletion of the transmembrane (TM)
region in Vpu (DelTM) resulted in a complete loss of FRET. Vpu
RD (URD) is a mutant which contains a randomized amino acid
sequence in the membrane spanning region and is therefore
impaired in the enhancement of viral particle release, but not in its
ability to degrade CD4 [27]. Strikingly, URD expressed together
with CD317 showed a strongly diminished FRET signal 14.5%
(+/23.8% SD). To the contrary, coexpression of URD and CD4
resulted in a wild-type like FRET signal 75.1% (+/218.7% SD). It
has been reported that the degree of Vpu colocalization with
CD317 correlates with functional repression of the restricting
activity on HIV-1 release [36]. Therefore, we assessed the
subcellular localization of the Vpu-YFP fusions together with
CD317-CFP and CD4-CFP (Fig. 3c). In agreement with the results
obtained by FRET, Vpu wild-type as well as US52A and UM2/6
colocalized with CD317 and CD4. DelTM lost its ability to localize
to membranes and was diffusely distributed inside the cells. In
contrast, URD colocalized with CD4, but not with CD317 (Fig. 3c).
To biochemically confirm the results of our FRET experiments we
performed co-immunoprecipitation experiments with CD317 and
the various Vpu mutants. As expected, CD317 co-immunoprecip-
itated with Vpu wild-type and the phosphorylation mutants US52A
undUM2/6,butnot with theDelTMorURDmutants(Fig.3d and
Fig. S4). In summary, these results support functional studies
[23,37] suggesting that Vpu binds CD4 with its alpha-helical
domain outside the TM region and targets it to proteasomal
degradation, a function that requires phosphorylation of serine
residues at positions 52 and 56 [23,37]. Moreover, our results
provide the first evidence that the Vpu/CD317 interaction is
mediated by specific residues in the TM region of Vpu and strongly
suggest that direct binding of Vpu to CD317 is necessary to
overcome its restricting activity on HIV-1 release.
Detection of Non-Membrane Localized Interactions by
FACS-FRET
Lentiviral Nef and Vpu proteins are mainly targeted to cellular
membranes and interact with other membrane associated recep-
tors or signalling complexes. To demonstrate that our assay is also
useful to investigate interactions of non-membrane bound proteins
we measured multimerization of the HIV-1 Rev protein, that is
important for the nuclear export of unspliced and incompletely-
spliced viral mRNAs [16]. CFP/YFP fusions of HIV-1 Rev were
able to mediate nuclear export of a Rev-responsive mRNA
reporter construct [19] and expression of the trans-dominant Rev
multimerization mutant SLT40 inhibited the biological activity of
wild-type Rev as previously reported [16] (Fig. S5). Co-expression
of CFP and YFP labelled Rev in 293T cells resulted in 66.2%
(+/27.5% SD) of FRET positive cells (Fig. 4a and b). As controls
and to verify our previous results that the assay is sensitive to
discriminate co-localization from FRET, we measured FACS-
FRET between Rev, the viral transactivator Tat and the
multimerization-deficient RevSLT40 mutant. As expected, we
did not measure significant FRET (Fig. 4a and b), despite strong
colocalization of these proteins in the cyto- and nucleoplasm, as
well as in nuclear microbodies (i.e. nucleoli) (Fig. 4c). In sum, these
results show the applicability of FACS-FRET to assess interactions
of non-membrane localized proteins.
FACS-Based FRET as a Tool for High-Throughput
Screening (HTS)
Mammalian- or yeast-two-hybrid assays are the most commonly
used methods to screen for protein interactions in vivo [1,2]. While
this technology is a powerful tool, FRET has the significant
advantage that it does not require the interaction to take place
within the nucleus. Therefore, we established FACS-based FRET
for HTS of protein interactions from a mixture of cDNAs (Fig. 5A).
Measuring FRET by FACS
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vector containing the ampicillin resistance gene [18]. Next, as
proof of principle, we mixed a cDNA library containing all the
cellular factors that have been analysed before (Fig. 2). Subse-
quently, we transfected 293T cells with the Vpu-YFP construct
and the mixture of CFP-fusions and sorted FRET+ cells. Prior to
sorting, 10.2% of cells transfected with the CFP-mixture and Vpu-
YFP scored FRET positive (Fig. 5B). Reanalysis of the sorted cell
fraction revealed that now 92.6% of cells exerted a FRET signal
(Fig. 5B), validating the purification of FRET+ cells.
Next, we performed the entire procedure with the mixed virtual
cDNA-library exactly as depicted in Fig. 5A. Using 293T cells and
CaCl transfection we were able to reisolate plasmids from down to
5,000 sorted cells. Restriction analyses of the plasmids revealed
that we isolated on average 50% to 60% of false positives together
with the Vpu binding partners, probably due to the presence of
multiple plasmids per cell and their amplification by the SV40
large t-antigen, which is constitutively expressed in 293T cells.
While the rate of false positives in our approach seems high at
first, it is acceptable in comparison to yeast-two-hybrid screens
which have an estimated number of false positives ranging from
50% up to 90% [38,39]. In sum, these results establish FACS-
based FRET as a useful tool to screen for protein interaction
partners from a cDNA mixture and warrant its application in
future high-throughput-screens.
Discussion
Our study describes a novel methodology to detect protein
interactions in living cells by combining FRET and flow
cytometry. Most importantly, compared to previous reports that
measured FRET by FACS [9,10,11,12,13], we designed an
approach that allows quantification and statistics, eliminates cross
talk artefacts and is easy to adapt to other applications. This
renders the method accessible to researchers that are not familiar
with FRET or complex FACS measurements. Moreover, by
employing biochemical methods (Fig. 3) we proved that our
FACS-FRET results reflect bona fide physical interactions that
can be detected in any cellular compartment (e.g. Nef at the
plasma-membrane; Vpu, which localizes to the plasma- and ER-
membrane and the trans-Golgi network, as well as Rev multimer-
formation in the cytosol, nucleus and nucleoli). We used a
standard equipped flow cytometer (FACSAria) and worked with
widely distributed cells, which are easy to cultivate and to transfect
(293T and HeLa cells, CaPO transfection and electroporation).
Furthermore, we established cloning strategies that allow the
generation of any gene of interest either as N- or C-terminal
fusions with the standard FRET pair ECFP or EYFP (Fig. S1).
An unique advantage of our approach is that FRET-efficiency
can easily be quantified as percentage of cells scoring FRET-
positive. The FRET signal is affected by numerous variables, e.g.
Figure 3. Vpu interacts with CD317 via its transmembrane region. (a) Representative primary FACS-plots showing the amount of FRET+ cells
in living 293T cells cotransfected with the indicated CD4 or CD317-CFP and Vpu-YFP fusion proteins. (b) Mean values and standard deviations (SD) for
the total amount of FRET+ cells from six independent experiments that were analysed as depicted in (a). (c) Confocal images of 293T cells that were
cotransfected with the Vpu-YFP fusion proteins (shown in green) and either CD317-CFP or CD4-CFP (shown in red). (d) 293T cells were transfected
with the indicated Vpu-YFP fusions and a FLAG-tagged CD317. Vpu immune complexes were isolated from cell detergent extracts by
immunoprecipitation with anti-Vpu rabbit serum and analysed for the presence of CD317 by Western blot with anti-FLAG.
doi:10.1371/journal.pone.0009344.g003
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expression and size of the fusion protein, quantity of interacting
proteins and, finally, distance between both interaction partners
[3,4]. Thus, the amount of FRET is a direct measurement of the
permanent proximity of two proteins inside a cell and is a strong
indicator for direct interaction. However, one has to be careful
when drawing conclusions from the FRET-efficiency on the
strength of an interaction. For example, our results show that HIV
Nef and Vpu as well as SIV Nef interact with CD4 qualitatively
(Fig. 2). Nevertheless, despite the higher FRET-efficiency of Vpu
together with CD4 we can not conclude that there is more or
stronger interaction, because the three dimensional architecture of
the Vpu fusion is fundamentally different from that of the Nef
fusions. On the other hand, the significant higher FRET-efficiency
of SIV Nef with CD3 suggests a stronger binding efficiency
compared to HIV-1 Nef (Fig. 2), since both proteins are
characterized by a comparable structure [22]. Importantly, this
result might explain conflicting reports concerning the ability of
HIV-1 Nef to bind to CD3 in the past [30,31]. Furthermore, in a
setting that keeps the variety of FRET parameters constant, we
could not only show that HIV-1 Vpu interacts with CD317 in
living cells, but also map functional interaction domains by FACS-
FRET (Fig. 3). Most interestingly VpuRD, a mutant that is
defective in the enhancement of HIV-1 particle release [27], was
unable to bind to CD317 but fully retained its ability to interact
with CD4. In agreement with a recent report [34], this strongly
suggests that interaction of Vpu with CD317 is functionally
required to overcome its restricting activity on HIV-1 release.
An inherent problem of FRET measurements is the required
tagging of proteins with fluorophores. For one, a tag may affect the
functionality and proper localization of proteins. In addition, the
spatial orientation of the proteins to be analysed might prevent the
fluorophores to come into close proximity, thereby preventing
emission of a FRET signal, despite ongoing protein-protein
interaction. False negative FRET signals could also be the result
of fusion protein interaction with endogenously expressed
interaction partners, reducing the overall FRET efficiency. This
could be the case for the putative interaction of Nef with MHC-I
[24], which could not be confirmed by FACS-FRET (Fig. 2). In
sum, negative FRET results do not allow to exclude the possibility
that two proteins interact. A positive FACS-FRET signal,
however, is a strong indicator for a physiological interaction in
vivo. In addition to the demonstration of such an interaction,
FACS-FRET offers a variety of down-stream applications, e.g.
mapping of interaction domains (Fig. 3) or screening for interfering
drugs and thus has the potential to give rise to new therapeutic
treating options for human diseases.
High-throughput-screening (HTS) for protein interactions is one
of the major bottlenecks in proteomics. The most frequently used
method, yeast-two-hybrid analyses, is a powerful tool, but also has
serious limitations. For example, post-translational modifications of
proteins in yeast are different from mammalian cells and inter-
actions have to take place in the nucleus [2]. Moreover, yeast-two-
hybrid screens are technically challenging and time consuming.
HTS by FACS-FRET has been demonstrated before, but only in
E.coli and due to the specific experimental setup and the used
chromophores it was only possible to perform the screen with small
fragments of a protein [13]. As proof of principle, we demonstrate
successful screening for full length interaction partners in living
mammalian cells by FACS-FRET (Fig. 5). Our false-positive rate
ranging from 50% to 60% is comparable or even better than the
estimates for yeast-two-hybrid screens [38,39,40]. Furthermore, it is
possible to render the screen morestringent by adjusting the FRET-
gate on the cost of isolatedcells. In ourexperiments we succeededto
Figure 4. Measurement of HIV-1 Rev multimerization by FACS-FRET. (a) Representative primary FACS-plots showing the amount of FRET+
cells in living 293T cells cotransfected with the indicated CFP and YFP fusion proteins. (b) Mean values and standard deviations (SD) for the total
amount of FRET+ cells from four independent experiments that were analysed as depicted in (a). (c) Confocal images of 293T cells that were
cotransfected with the indicated YFP (shown in green) and CFP (shown in red) fusion proteins.
doi:10.1371/journal.pone.0009344.g004
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it must be noted that with such low cell numbers the total yield of
plasmids was rather low ranging around 30 colonies. Thus, for a
true screen it is required to sort substantially more cells. As already
mentioned, the high amount of false-positives is probably due to
multiple plasmids that are transfected per cell and which are
subsequently reisolated along with the ‘‘true’’ hits. We tried to avoid
this problem by reducing the amount of DNA and changing the
method of DNA delivery (e.g. electroporation). However, this
measures always resulted in a significant loss of recovered DNA.
Current experiments in our lab focus on the improvement of the
screen by (i) the evaluation of novel chromophores that might have
an improved FRET-efficiency, (ii) testing of other cells and
transfection methods and (iii) alternative approaches to reisolate
the plasmids from the sorted cells. Nevertheless, we also currently
exploit the screen as it is presented in this report to identify novel
interaction partners of HIV-1 proteins from a cloned T-cell cDNA
library.
Altogether, FACS-FRET has several significant advantages
compared to existing methods. It allows to detect protein inter-
actions in all cellular compartments, it is fast and quantitative,
non-invasive and highly reproducible. Thus, the FACS-based
FRET assay presented herein may significantly improve our
prospects to define protein interactions in living mammalian cells.
Supporting Information
Figure S1 Expression vectors for the generation of fusion
proteins. Unmodified pEYFP- or pECFP-C1/N1 (Clontech)
vectors were chosen for the generation of fusion proteins. C-
terminal with chromophore tagged fusions can be generated in
either the C1 or the N1 vector backbone by using single NheI and
AgeI restriction sites. The gene of interest (GOI) is cloned in frame
with the chromophore post elimination of the stop codon and
introduction of the linker sequence GAGAPVAT by PCR. N-
terminal with chromophore tagged fusions can be generated in the
Figure 5. High-throughput-screening for unknown protein interactions by FACS-FRET. (a) Experimental setup to screen for unknown
protein interaction with flow cytometry based FRET in high-throughput. (b) Living 293T cells were transfected with the Vpu-YFP fusion as a bait and a
mixture of equal amounts of the CFP-fusion constructs that are described in Figure 2. 36 h post transfection FRET+ cells were sorted, pelleted,
resuspended in PBS and reanalysed for successful purification. Abbreviation GOI, gene of interest.
doi:10.1371/journal.pone.0009344.g005
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using BsrGI and NotI together with the linkers indicated.
Found at: doi:10.1371/journal.pone.0009344.s001 (0.27 MB TIF)
Figure S2 Analyses of cell surface receptor modulation by Nef
and Vpu fusion proteins. Jurkat cells were electroporated with
pEYFP-only, pEYFP-MEM, pEYFP HIV-1 NA7 Nef, pEYFP-
SIV mac239 Nef or pEYFP-NL4-3 Vpu and down-modulation of
CD4, CD3 and MHC-I by the different viral proteins was
measured by flow cytometry as described in the methods section.
Receptor cell surface expression of pEYFP-only electroporated
cells was set as 100%. Presented are means and standard
deviations of two independent experiments.
Found at: doi:10.1371/journal.pone.0009344.s002 (0.23 MB TIF)
Figure S3 Colocalization and subcellular localization of viral
and cellular fusion-proteins. Confocal images of 293T cells that
were cotransfected with the indicated YFP- and CFP-fusion
proteins. The top panel shows three different cells that were
transfected with the indicated YFP-fusion proteins only. The left
panel shows individual cells that were transfected with the
indicated CFP-fusion proteins only. YFP is shown in green and
CFP is shown in red.
Found at: doi:10.1371/journal.pone.0009344.s003 (2.36 MB TIF)
Figure S4 Untagged NL4-3 Vpu protein immunoprecipitates
CD317. 293T cells were transfected with the pCG-NL4-3 Vpu
and a FLAG-tagged CD317. Vpu complexes from cellular lysates
were immunoprecipitated with a rabbit anti-Vpu serum (43) and
blotted for the presence of CD317 with anti-FLAG.
Found at: doi:10.1371/journal.pone.0009344.s004 (0.23 MB TIF)
Figure S5 Biological activity of HIV-1 Rev CFP/YFP fusion
proteins. 293T cells were transfected with the indicated CFP/YFP
fusion proteins and co-transfected with the Gag expression vector
GPV-RRE (36) and a CMV-SEAP reporter construct. Released
p24 was measured by ELISA and normalized to transfection
efficiency by determining the levels of SEAP (secreted alkaline
phosphatase). Error bars represent the SD of triplicates from one
representative out of two independent experiments.
Found at: doi:10.1371/journal.pone.0009344.s005 (0.19 MB TIF)
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